and BioNTech said that they had selected a lead vaccine candidate from within a broader development programme and will proceed with a later-stage safety and efficacy trial of the experimental shot in a two-dose regimen. The announcement came in anticipation of Pfizer
reporting second-quarter earnings on Tuesday.
Governments around the world are now looking to lock up supplies of the still-experimental candidates.
Each has hopes of stabilising local economies and stopping spread of the virus that’s taken more than 650,000 lives globally. Last week, Pfizer and BioNTech clinched a $2 billion deal to supply an initial 100 million doses of a vaccine to the US. That set a price ceiling of less than $20 per dose, which will likely impact how much others will charge.